Apimeds gets NYSE American delisting notice for late 10-K; trading halt continues

Apimeds Pharmaceuticals US, Inc.

Received NYSE American notice on April 17, 2026 for failure to file 2025 10-K on time.
Has initial 6-month cure period until October 15, 2026; expects to file 10-K by April 30.
Common stock trades with '.LF' designation; trading halt from April 2 remains in effect.
If not cured, NYSE may grant up to 6 additional months or commence delisting procedures.

item 3.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.